Company profile: Symphogen
1.1 - Company Overview
Company description
- Provider of recombinant polyclonal antibody drugs and platforms for disease treatment and prevention. Offers Symplex PCR cloning for antigen-specific antibodies, an antibody discovery and research platform focused on oncology and immuno-oncology, and CMC processes for manufacturing. Pipeline includes Sym013 (pan-HER antibody mixture) and Sym021 (anti-PD-1) with combinations Sym022 (anti-LAG-3) and Sym023 (anti-TIM-3).
Products and services
- Antibody Discovery and Research Platform: An oncology-focused platform that architects differentiated antibody therapeutics, supporting discovery and early development primarily in oncology and immune oncology
- Symplex: A proprietary PCR method that engineers cloning of antigen-specific antibodies from single sorted B cells, enabling expression and screening of full-length antibodies for optimal properties
- Sym013: A recombinant pan-HER antibody mixture being explored in a first-in-human trial to evaluate safety, antitumor activity, and pharmacokinetics in advanced epithelial malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Symphogen
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
Mythic Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology-based cancer therapeutics, including MYTX-011, an investigational cMET-targeting antibody-drug conjugate designed to increase delivery of chemotherapy to cancer cells while reducing uptake in healthy cells; FateControl™, a platform that enhances ADC uptake in cancer cells and minimizes payload release in normal cells to improve potency and tolerability; and KisMET-01, a Phase 1 trial in NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mythic Therapeutics company profile →
BioVex
HQ: United Kingdom
Website
- Description: Provider of biological treatments for cancer and infectious diseases, focused on development and commercialization. Its cancer program includes OncoVEXGM-CSF, an oncolytic vaccine/cancer-destroying virus that replicates and spreads within solid tumors, causing tumor destruction, and it advances biological treatments for the prevention of infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVex company profile →
Genoptix
HQ: United States
Website
- Description: Provider of specialized oncology diagnostics services, regularly participating in industry conferences to share findings, discuss emerging solutions, and create connections that advance the oncology community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genoptix company profile →
GPC Biotech
HQ: Germany
Website
- Description: Provider of anticancer drug discovery and development as a German biopharmaceutical company. Portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GPC Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Symphogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Symphogen
2.2 - Growth funds investing in similar companies to Symphogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Symphogen
4.2 - Public trading comparable groups for Symphogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →